Tucatinib: Ph II HER2CLIMB amended

Cascadian (formerly Oncothyreon Inc.) amended the double-blind, placebo-controlled, international Phase II HER2CLIMB trial of oral tucatinib to increase enrollment to 480 patients from 180, allowing H...